Rachel Cohrs, STAT

Rachel Cohrs


Washington, DC, United States

Contact Rachel

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Unknown
  • STAT
  • The Dallas Morning News
  • The Sacramento Bee
  • TriCityHerald

Past articles by Rachel:

Biden administration requests $20 billion cash infusion to bolster public health

The Biden administration is calling for a big boost for public health funding across the federal health department, but left out specific funding for Covid-19 activities. → Read More

An unlikely new 340B alliance emerges between PhRMA and community health centers

The alliance says the federal drug discount program has expanded beyond its original mission to help low-income populations, and instead is benefiting large, well-resourced hospitals. → Read More

Pfizer CEO Albert Bourla maxed out campaign contributions to Dr. Oz ahead of midterm elections

Pfizer CEO Albert Bourla made the maximum possible campaign contribution to Mehmet Oz ahead of his failed bid to represent Pennsylvania in the U.S. Senate. → Read More

Biden proposes expanding Medicare drug negotiation program

The Biden administration wants to expand Democrats’ new drug pricing law by allowing Medicare to negotiate prices for more drugs. → Read More

How can states keep people insured after Medicaid protections lapse? Connecticut has an idea

Connecticut officials recruited diverse candidates to ensure people in underserved communities have access to advice about health insurance ahead of a major Medicaid transition. → Read More

What is basal cell carcinoma, the skin cancer Biden just had

“If you have to get cancer, it’s kind of a good one to have because it’s easy to remove," an oncologist said about President Biden's case. "This is an easily curable cancer that should not impact one’s quality of life, prognosis, or survival.” → Read More

Biden administration pitches 3 big new drug pricing reform experiments

The Biden administration is pitching three new experiments aimed at bringing down drug prices for Medicare and Medicaid patients. → Read More

Medicare advisers suggest tweaks to coverage process for Alzheimer’s drugs

Medicare advisers want to tweak a process that has been used to restrict access to new Alzheimer’s drugs. → Read More

Sen. Tammy Baldwin criticizes Ascension’s for-profit investment activities, requests returns and fees info

Citing STAT's reporting, Sen. Tammy Baldwin questioned whether Ascension is using the returns from its for-profit investments to help patients. → Read More

Medicare details forthcoming penalties for drug price hikes

The Biden administration offered the first glimpse into how it’s planning to enact a new law that will penalize drugmakers for hiking their prices faster than inflation. → Read More

What people on Medicare can expect once the Covid-19 public health emergency ends

Medicare enrollees will pay more for Covid tests after the public health emergency ends, according to the agency that oversees the program. → Read More

How one biotech investor is changing his calculus now that Medicare can negotiate drug prices

Biotech investors don’t often lay out their strategies, but one offered a rare glimpse into what he's doing after Democrats empowered Medicare to negotiate drug prices. → Read More

Former Sen. Richard Burr to join health care practice at law and lobbying firm

Former Senate health committee Republican leader Richard Burr will be starting a new health care practice at a well-known Washington law and lobbying firm. → Read More

New York’s hospitals are poised for political power this Congress

As hospitals worry that payments from federal health programs could be slashed, the New York lobby's relationships could come in handy. → Read More

The unexpected alliance lobbying for Medicare to pay for new obesity drugs

WASHINGTON — It’s not every day that the pharmaceutical industry, the NAACP, a cancer center, and a nonpartisan think tank are all lobbying to achieve the → Read More

PhRMA terminates lobbying contract with White House official’s brother

PhRMA has terminated its contract with Jeff Ricchetti, a lobbyist who is the brother of a prominent Biden White House official. → Read More

HHS needs better oversight of research that alters pathogens, government watchdog says

HHS oversight of research that could enhance dangerous pathogens has vague parameters and a lack of transparency, a federal watchdog found. → Read More

HHS will seek more input on its new Medicare drug price negotiations

HHS laid out a detailed timeline of when the public can weigh on on the agency’s new Medicare drug price negotiation program. → Read More

Will America’s public health reckoning ever come?

Despite the many failures of our Covid response, very little about U.S. pandemic infrastructure has changed. But some are still working to find compromise reforms. → Read More

HHS will decide how to resolve $1 billion in payments for 340B hospitals

HHS will get to decide how to pay hospitals in the 340B program for more than $1 billion in illegal underpayments, a federal court ruled. → Read More